论文部分内容阅读
探讨整合蛋白α５与肝癌某些临床病理特征的关系。方法应用免疫组化技术（ＡＢＣ法）检测整合蛋白α５亚基在７９例原发性肝癌组织及其相应癌周组织中的表达。结果癌组织及其相应癌周组织中α５阳性率分别为３２．９％和８１．０％，差异有非常显著意义（Ｐ＜０．０１）。直径≤５ｃｍ的小肝癌α５阳性率高于直径＞１０ｃｍ的大肝癌（分别为５５．６％，１０．０％，Ｐ＜０．０１）；分化较好的肝癌，α５阳性率高于分化不良者（分别为４０．６％、１６．０％，Ｐ＜０．０５）；已发生包膜侵犯和肝内转移的侵袭性肝癌，其α５阳性率低于包膜未受侵犯和无发生肝内转移的肝癌（分别为１６．０％、６８．７％，２０．４％、４２．２％）。α５亚基表达与患者年龄、血清甲胎蛋白水平、ＨＢＶ感染、肝硬化等因素均无显著相关（Ｐ＞０．０５）。结论整合蛋白α５低表达与肝癌生长、低分化、包膜侵犯、肝内侵袭转移发生及病情进展相关，可能是肝癌的一种负性调节因子。
To explore the relationship between integrin α5 and some clinicopathological features of liver cancer. Methods Immunohistochemical technique (ABC method) was used to detect the expression of integrin α5 subunit in 79 cases of primary hepatocellular carcinoma and their corresponding tissues. Results The positive rates of α5 in cancer tissues and their corresponding tissues were 32.9% and 81.0%, respectively. The difference was significant (P<0.01). The positive rate of α5 in small hepatocellular carcinoma with diameter ≤5cm was higher than that in large hepatocellular carcinoma with diameter >10cm (55.6%, 10.0%, P<0.01). The positive rate of α5 in hepatocellular carcinoma with better differentiation was higher than that in poor differentiation. (40.6%, 16.0%, P<0.05, respectively); Invasive hepatocellular carcinoma with envelop invasion and intrahepatic metastasis, the α5 positive rate was lower than that of the capsule without invasion and no liver Liver metastases (16.0%, 68.7%, 20.4%, 42.2%, respectively). The expression of α5 subunit was not significantly associated with age, serum alpha-fetoprotein level, HBV infection, and cirrhosis (P>0.05). Conclusion The low expression of integrin α5 is associated with the growth, poor differentiation, capsule invasion, intrahepatic invasion and metastasis, and progression of liver cancer. It may be a negative regulator of liver cancer.